More than 20 billion yuan of anti-anemia drug market, domestic pharmaceutical companies are actively layout

Clinically, anemia generally means that the concentration of hemoglobin in the peripheral blood is lower than the normal standard
of the same age group, the same sex and the same region of the patient.
Anemia is mainly divided into five categories: iron deficiency anemia, hemorrhagic anemia, hemolytic anemia, megaloblastic anemia and aplastic anemia, of which iron deficiency anemia is a particularly common type
in clinical practice.
Children, women, pregnant women and the elderly are among the most common people
with anaemia.
Data show that at present, the incidence of anemia in people over 65 years old in China exceeds 20%, of which the incidence of anemia in the elderly over 85 years old is higher
.
The National Nutrition Plan (2017-2030) points out that reducing the rate of anaemia among the population is one of the important goals of
residents' nutrition and health in the next ten years.
Under the background of population aging, the total scale of China's anti-anemia drug market has maintained steady growth, reaching 26.
45 billion yuan in 2021, and it is expected that the scale of China's anti-anemia drug market will reach 26.
975 billion yuan
in 2022.
In the face of considerable market space, many domestic pharmaceutical companies have actively deployed, and new actions and good news have continued since
the beginning of this year.
For example, on June 21, Jiudian Pharmaceutical issued an announcement that the company recently received the "Drug Supplement Application Approval Notice" approved and issued by the State Medical Products Administration, and the company's product "ferrous succinate tablets" passed the quality and efficacy consistency evaluation
of generic drugs.
Ferrous succinate tablets are a commonly used and safe and effective drug
for the prevention and treatment of iron deficiency anemia.
As of the date of this announcement, the company is the second enterprise
in China to pass the consistency evaluation of ferrous succinate tablets.
On May 10, Hansen Pharmaceutical announced that the marketing authorization application for a new indication for the Class 1 innovative drug "Pemosadide Injection" (original name: Peihua West Hippocampide Injection) independently developed by its subsidiary Haosen Pharmaceutical was accepted by the State Food and Drug Administration for the treatment of anemia
in non-dialysis chronic kidney disease patients who did not receive erythropoietin treatment 。 In March, 3SBio announced that the recombinant erythropoiesis stimulating protein injection (rESP, CHO cells) developed by the company is currently undergoing a "multicenter, randomized, parallel controlled phase III clinical trial comparing the efficacy and safety of intravenous injection of recombinant erythropoiesietic stimulating protein injection (CHO cells) and EPEO in hemodialysis patients with chronic renal failure anemia", and has recently completed the enrollment of the first subject and successfully completed the first dose according to the protocol
。 On January 4, Salubris submitted an application for the marketing of
three types of generic enastat tablets.
IT IS REPORTED THAT THE PRODUCT WAS INTRODUCED BY THE COMPANY FROM JAPAN TOBACCO INC.
IN JAPAN IN 2019, IS AN ORAL SMALL MOLECULE INNOVATIVE PREPARATION FOR ANTI-RENAL ANEMIA, AND THE INDICATIONS DEVELOPED ARE RENAL ANEMIA
.
If successfully approved for marketing, the drug will become the second HIF-PHI (prolylylhydroxylase inhibitor) drug
to be marketed in China.
Some securities firms have predicted that the peak sales of onastat tablets are expected to exceed 3 billion yuan
.
In addition, in February this year, Xidian Pharmaceutical, the leading enterprise of anti-anemia drugs in China, was listed
.
It is reported that the company is involved in both APIs and pharmaceutical preparations two tracks, the company currently ninety percent of its revenue comes from pharmaceutical preparations, core products include compound ferrous sulfate folic acid tablets (trade name "Yiyuansheng"), risperidone oral collapse tablets (trade name "Ketong"), respectively anti-anemia drugs, antipsychotic drugs, the sales revenue of the two drugs accounted for more than eighty percent of its overall revenue, and the market share in the track is not low
。 In addition to the above-mentioned pharmaceutical companies, domestic pharmaceutical companies such as Zhendong Pharmaceutical also have a market of tens of billions of anti-anemia drugs, and with the advancement and approval of more new drugs, it will bring more new treatment options
to the majority of anemia patients in China.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice
to anyone.